MX2018012018A - Composicion para el tratamiento de la distrofía muscular de duchenne. - Google Patents

Composicion para el tratamiento de la distrofía muscular de duchenne.

Info

Publication number
MX2018012018A
MX2018012018A MX2018012018A MX2018012018A MX2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A MX 2018012018 A MX2018012018 A MX 2018012018A
Authority
MX
Mexico
Prior art keywords
muscular dystrophy
treatment
composition
duchenne muscular
asds
Prior art date
Application number
MX2018012018A
Other languages
English (en)
Inventor
Horne Graeme
Original Assignee
Summit Oxford Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1605383.7A external-priority patent/GB201605383D0/en
Priority claimed from GBGB1612920.7A external-priority patent/GB201612920D0/en
Application filed by Summit Oxford Ltd filed Critical Summit Oxford Ltd
Publication of MX2018012018A publication Critical patent/MX2018012018A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Se describen dispersiones sólidas amorfas (asd) que comprenden el compuesto 5-(etilsulfonil)-2-(naftalen-2-il)venzo[d]oxasol (ezutromid) y un polímero. Los ASDs encuentran aplicación en el tratamiento o la profilaxis de la distrofia muscular de Duchene y distrofia muscular de Becker.
MX2018012018A 2016-03-30 2017-03-29 Composicion para el tratamiento de la distrofía muscular de duchenne. MX2018012018A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1605383.7A GB201605383D0 (en) 2016-03-30 2016-03-30 Composition for the treatment of duchenne muscular dystrophy
GBGB1612920.7A GB201612920D0 (en) 2016-07-26 2016-07-26 Composition for the treatment of Duchenne Muscular Dystrophy
PCT/GB2017/050884 WO2017168151A1 (en) 2016-03-30 2017-03-29 Composition for the treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
MX2018012018A true MX2018012018A (es) 2019-07-04

Family

ID=58640913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012018A MX2018012018A (es) 2016-03-30 2017-03-29 Composicion para el tratamiento de la distrofía muscular de duchenne.

Country Status (11)

Country Link
US (1) US20200016076A1 (es)
EP (1) EP3500245A1 (es)
JP (1) JP2019510056A (es)
KR (1) KR20190026647A (es)
CN (1) CN109803641A (es)
AU (1) AU2017243198A1 (es)
BR (1) BR112018070076A2 (es)
IL (1) IL262013A (es)
MX (1) MX2018012018A (es)
PH (1) PH12018502276A1 (es)
WO (1) WO2017168151A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
WO2007091106A2 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CN101678107A (zh) * 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
GB0715937D0 (en) 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
GB201208178D0 (en) 2012-05-10 2012-06-20 Summit Corp Plc Pharmaceutical composition for the treatment of duchenne muscular dystrophy
WO2014182710A1 (en) 2013-05-06 2014-11-13 The Regents Of The University Of Minnesota Sugar containing, amphiphilic copolymers
GB201412010D0 (en) * 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia

Also Published As

Publication number Publication date
CN109803641A (zh) 2019-05-24
AU2017243198A1 (en) 2018-11-22
IL262013A (en) 2018-12-31
EP3500245A1 (en) 2019-06-26
KR20190026647A (ko) 2019-03-13
PH12018502276A1 (en) 2019-09-09
JP2019510056A (ja) 2019-04-11
WO2017168151A1 (en) 2017-10-05
US20200016076A1 (en) 2020-01-16
BR112018070076A2 (pt) 2019-05-21

Similar Documents

Publication Publication Date Title
EP3452498A4 (en) CRISPR / CAS RELATED METHODS AND COMPOSITIONS FOR TREATING DUCHENNE MUSCLE DYSTROPHY
EP3191533A4 (en) Polymers including one or more 1,1-disubstituted alkene compounds and polymer compositions thereof
EP3428196A4 (en) ORGANIC SILICON COMPOUND, AND RUBBER COMPOUNDING AGENT AND RUBBER COMPOSITION THEREWITH
EP3220741A4 (en) Composition and kits for inhibition of pathogenic microbial infection and methods of using the same
EP3218484A4 (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
MX2015017044A (es) Composiciones y metodos para tratar el cabello.
EP3364968A4 (en) OXAZOLIDINONE COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS
EP3160278A4 (en) Glove having durable ultra-thin polymeric coating
MX2018015657A (es) Compuestos heterociclico como antibacterianos.
EP3207048A4 (en) Compositions and methods of treating muscular dystrophy
EP3399993A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING DUCHENNE MUSCLE DYSTROPHY
EP3190100A4 (en) Polymerizable compound, polymer, polymerizable composition, and film
EP3124511A4 (en) Nitrile group-containing copolymer rubber, crosslinkable rubber composition and crosslinked rubber product
EP3635573A4 (en) PERFORMING HASH CONNECTIONS USING PARALLEL PROCESSING
EP3646352A4 (en) POLYMERIC COMPOSITION INTENDED FOR USE IN CABLES
EP3655404A4 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF MICROBIAL INFECTIONS
EP3645655A4 (en) POLYMER-LIQUID COMPOSITES TO IMPROVE ANTI-FOULING PERFORMANCE
EP3466996A4 (en) ORGANIC SILICON COMPOUND, RUBBER ADDITIVE, AND RUBBER COMPOSITION USING THE SAME
EP3161043A4 (en) Modified fillers for rubber compounding and masterbatches derived therefrom
SG10201901705RA (en) High torque polymer fittings
MX353406B (es) Composiciones y metodos para tratar el cabello.
EP3590923A4 (en) COMPOUND BASED ON DIARYLAMINE, ANTI-AGING AGENT AND POLYMER COMPOSITION
EP3481425A4 (en) DEPLOYMENT OF CYSTINE MEDIATED BY A HUMAN ENZYME FOR THE TREATMENT OF PATIENTS WITH CYSTINURIA
EP3299398A4 (en) Copolymer for use as polymer blend compatibilizer, and resin composition
EP3190893A4 (en) Compositions and methods for treating and preventing bacterial infections